BioSpace News Archive

Aphaia Pharma today announced that it has completed enrollment in its Phase 2 trial evaluating the safety and efficacy of a once-daily 12g dose of its oral glucose formulation (APHD-012) to induce weight loss in individuals with obesity.

Starton Therapeutics Inc. (“Starton” or the “Company”), a clinical-stage biotechnology company transforming standard-of-care therapies with proprietary dermal technologies, announced today the successful completion of enrollment for its STAR-LLD Phase 1b clinical trial in multiple myeloma.

NurExone Biologic Inc., a pioneering biopharmaceutical company is pleased to announce that its common shares are now quoted for trading on the OTCQB® Venture Market under the symbol NRXBF.

Owlstone Medical (“Owlstone”), the global leader in Breath Biopsy® for applications in early disease detection and precision medicine, today announced it has secured funding from the Bill & Melinda Gates Foundation (“the Gates Foundation” or “the foundation”).

Kura Oncology, Inc. today announced that it will report first quarter 2024 financial results after the close of U.S. financial markets on Thursday, May 2, 2024.

Accuray Incorporated (NASDAQ: ARAY) announced today that the company is showcasing advances in hardware and software designed to improve the cancer treatment experience.

Soligenix, Inc. announced that it has received notice of intent to grant additional patents based on its patent application titled “Compositions and Methods of Manufacturing Trivalent Filovirus Vaccines” in the United Kingdom and South Africa, with other international jurisdictions pending.

AMRA Medical in collaboration with Linköping University, is pleased to announce the completion of baseline enrollment for the innovative ACCESS-ESLD study.

Freedom Biosciences, Inc. (“Freedom Bio” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has notified the Company that it may proceed with its FREE001-TRD-201 study for its lead program, FREE001, a ketamine-based combination therapy for the treatment of treatment-resistant depression (TRD).

Inspira™ Technologies announced that it has received the Canadian Standards Association (CSA) Certification of Compliance to U.S. standards for the INSPIRA ART100 device.